ANAVEX®2-73 (BLARCAMESINE) PHASE 2B/3 STUDY MET PRIMARY AND KEY SECONDARY ENDPOINTS,

Anavex Life Sciences Reports Fiscal 2022 Year End Financial Results and Provides Business Update

Anavex Life Sciences Announces Late-Breaking Presentation at the 2022 CTAD Congress

Anavex Life Sciences new U.S. Patent ANAVEX®2-73 (blarcamesine) for Neurodevelopmental Disorders

Anavex Reports Publication in Medical Journal Highlighting the Relevance of SIGMAR1 Activation in AD

Long-lasting Effect of ANAVEX®3-71 Prevents Cognitive Decline in Animal Model of AD at AAIC 2022

Anavex Announces First Entire Clinical Alzheimer’s Gene Pathway Data of ANAVEX®2-73 at AAIC 2022

Anavex Life Sciences Announces Its Very First Scientific Educational Video News Release

Data Review by the Independent DSMB reported for Phase 2b/3 Trial of ANAVEX®2-73 for AD

Anavex Life Sciences Announces ANAVEX®2-73 Significantly Prevented Aβ (Abeta)-induced Deficits

Anavex Life Sciences Reports the Mechanism of ANAVEX®2-73 (blarcamesine) and ANAVEX®3-71 (AF710B)

Anavex Life Sciences Announces Exceeding of Enrollment Target for the Precision Medicine ANAVEX®2-73

Anavex Life Sciences Announces Notice of Allowance for U.S. Patent Application ANAVEX®2-73

Anavex Life Sciences Reports Data Review by the Independent Data Safety Monitoring Board

Anavex Life Sciences Reports ANAVEX®2-73 featured as a Disease-Modifying Small Molecule in Trials

Anavex Life Sciences Receives TGA Special Access Scheme Approval for ANAVEX®2-73 for Alzheimer’s

Anavex Life Sciences Receives Approval from Health Canada & UK MHRA Expanding Phase 2b/3 ANAVEX®2-73